As of November 7, 2026, Senti Biosciences Holdings, Inc. has reported 2 leadership change filings to the SEC under Item 5.02 of Form 8-K, from September 24, 2026 to October 27, 2026, naming 2 departures. The latest filing names Edward Mathers, leaving (Form 8-K, October 27, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Senti Biosciences Holdings, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Senti Biosciences Holdings, Inc. reported changes in 2 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-09-24 to 2026-10-27. They name 2 people. Every row below is cited to the filing it comes from, and this page adds each new change as Senti Biosciences Holdings, Inc. files it.
Also on the record for Senti Biosciences Holdings, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| September 11, 2026 | Stake report, Schedule 13D/A, by Celadon Partners SPV 24 | 54.6% of the class | 5%+ stakes | Source |
| July 16, 2026 | Stake report, Schedule 13D/A, by Celadon Partners SPV 24 | 54.6% of the class | 5%+ stakes | Source |
| June 4, 2026 | Form D, private offering | $10M sold | Form D page | Source |
| May 4, 2026 | Stake report, Schedule 13D/A, by Celadon Partners SPV 24 | 54.6% of the class | 5%+ stakes | Source |
| April 16, 2026 | Stake report, Schedule 13D/A, by Bayer HealthCare LLC | 17.82% of the class | 5%+ stakes | Source |
| March 31, 2026 | Stake report, Schedule 13D/A, by New Enterprise Associates 15, L.P. | 12.1% of the class | 5%+ stakes | Source |
| January 20, 2026 | Stake report, Schedule 13D/A, by Celadon Partners SPV 24 | 45% of the class | 5%+ stakes | Source |
| September 2, 2025 | Stake report, Schedule 13D/A, by Celadon Partners SPV 24 | 45% of the class | 5%+ stakes | Source |
| December 19, 2024 | Form D, private offering | $37.60M sold | Form D page | Source |
Selling to them or working with them? See who runs Senti Biosciences Holdings, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Senti Biosciences Holdings, Inc. and the records around it.
Senti Biosciences Holdings, Inc. elsewhere on the record
- 5%+ stake filings Sep 2026
- Company profile and every filing Jun 2026
- Form D filing Jun 2026
- Who owns it
Companies that share a holder
- New Enterprise Associates 15, L.P. also filed stake reports on 1 other company: Arcellx, Inc. (Apr 2026)
Watch Senti Biosciences Holdings, Inc.
Get an email when Senti Biosciences Holdings, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Senti Biosciences Holdings, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Senti Biosciences Holdings, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Senti Biosciences Holdings, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
11 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-10-27 | Out | 8-K, 2026-10-27 | |||
| 2026-09-24 | Out | 8-K, 2026-09-24 |
New leaders reset buying decisions — get the Full Report on Senti Biosciences Holdings, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportWatch Senti Biosciences Holdings, Inc. (free up to 3)
Find people with the same kind of experience as the senior executive at Senti Biosciences Holdings, Inc., with the record behind each one.
Find candidates like senior executive at Senti Biosciences Holdings, Inc.Every change, in the filing's words
Departing: Edward Mathers
On October 27, 2026, Edward Mathers notified the Board of Directors (the "Board") of Senti Biosciences Holdings, Inc. (the "Company") of his decision to resign from the Board, effective immediately.
- In connection with his resignation from the Board, Mr. Mathers also resigned from all committees of the Board on which he served, effective immediately.
- The Company thanks Mr. Mathers for his valuable contributions and dedicated service to the Company and the Board and wishes him the best in his future endeavors.
Departing: Brenda Cooperstone
On September 23, 2026, Brenda Cooperstone, Ph.D., notified the Board of Directors (the "Board") of Senti Biosciences Holdings, Inc. (the "Company") of her decision to resign from the Board, effective immediately.
- In connection with her resignation from the Board, Dr. Cooperstone also resigned as a member and Chair of the Compensation Committee of the Board, effective immediately.
- Dr. Cooperstone's resignation was not the result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices.
- The Company thanks Dr. Cooperstone for her valuable contributions and dedicated service to the Company and the Board and wishes her the best in her future endeavors.
Senti Biosciences Holdings, Inc.'s funding history
Tools for this story
Each opens in a new tab, filled in for Senti Biosciences Holdings, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.